Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
March 10, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
Music of Your Life Launches Street Talk
March 07, 2025 10:59 ET
|
The Marquie Group, Inc.
TMGI subsidiary Music of Your Life launches syndicated radio program as company continues focuse on cancer awareness.
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
March 07, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda
Plus Therapeutics Announces New Employment Inducement Grants
March 05, 2025 16:01 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces New Employment Inducement Grants
Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders
March 05, 2025 12:15 ET
|
Siren Biotechnology, Inc.
Siren Biotechnology expands Clinical and Scientific Advisory Board with key industry leaders
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
March 04, 2025 14:06 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
Irazú Oncology Secures Bridge Funding, Expands Leadership Team and Facilities
March 04, 2025 08:30 ET
|
Irazu Oncology
Dr. Mayukh Das, joined Irazú as CMO, bringing extensive oncology drug development experience from leadership roles at global pharmaceutical companies.
Tumor Ablation Market to Reach $7.5 billion, Globally, by 2035 at 13.6% CAGR: Allied Market Research
March 04, 2025 06:30 ET
|
Allied Market Research INC
Wilmington, Delaware, March 04, 2025 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Tumor Ablation Market by Technology (Radiofrequency Ablation, Microwave Ablation,...
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
February 27, 2025 16:05 ET
|
Cardiff Oncology, Inc.
- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) - - Priced oversubscribed $40...
KFNCCC Welcomes Georgina Rodríguez's Visit to Support Young Cancer Patients
February 27, 2025 06:51 ET
|
King Faisal Specialist Hospital & Research Centre
KFNCCC Welcomes Georgina Rodríguez's Visit to Support Young Cancer Patients